SCHEMBL2163174

SCHEMBL2163174

CC1OCc2sc(NC(=O)C3=CC(=O)CC(C)(C)O3)c(C(=O)C3CCC3)c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.37
CNR2 P34972 2/20 0.37
ALDH1A1 P00352 5/20 0.36
RAB7A P51149 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.32
MAPT P10636 4/20 0.32
KMT2A Q03164 3/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
MEN1 O00255 2/20 0.32
KDM4E B2RXH2 2/20 0.32
ATM Q13315 2/20 0.32
LMNA P02545 2/20 0.30
HPGD P15428 2/20 0.30
CFTR P13569 1/20 0.30
GAA P10253 1/20 0.30
TSHR P16473 1/20 0.30
CASP1 P29466 1/20 0.30
HSD17B10 Q99714 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162128 0.77 CNR2 (0.44) CNR1CNR2ALDH1A1RAB7ASMN1; SMN2
SCHEMBL2162410 0.72 CNR1 (0.46) CNR1CNR2ALDH1A1KDM4EL3MBTL1
SCHEMBL2162492 0.71 NPC1 (0.42) CNR1CNR2MAPTKMT2ANPC1
SCHEMBL2162358 0.70 CNR2 (0.50) CNR1CNR2MAPTKDM4EHPGD
SCHEMBL2162140 0.70 MAPT (0.46) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL2163738 0.70 CNR2 (0.47) CNR1CNR2
SCHEMBL2162393 0.70 CNR1 (0.38) CNR1CNR2ALDH1A1SMN1; SMN2MAPT
SCHEMBL2162482 0.70 CNR2 (0.52) CNR1CNR2KMT2A
SCHEMBL2162421 0.69 CNR2 (0.50) CNR1CNR2MAPTKDM4EHPGD
SCHEMBL2162362 0.68 CNR2 (0.47) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US claimed
WO-2008028094-A1 COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 WO claimed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US claimed
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US disclosed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US disclosed
WO-2008028094-A1 COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, OPRL1 CNR1 1/4885CNR2 2/4885ALDH1A1 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.